Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2026-01-25 @ 3:44 AM
Study NCT ID:
NCT05285904
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-01
First Post:
2022-03-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
Sponsor:
Novartis Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
COMB157GCH01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None